COVID-19 has been the reason for the pandemic, which is induced by the SARS-CoV-2. Potential drugs are being used for its cure, but there's no specific drug for it. To get a specific drug, many drug designing strategies are being used in which molecular docking plays a vital role in computer-assisted drug designing. The aim of this study was to develop an appropriate anti-viral drug against the SARS-CoV-2 virus. In this research, we've tested the molecular docking of Lopinavir (LV), Ritonavir, Zanamivir, Peramivir, Atazanavir, Daclatasvir, Raltegravir on the Receptor Binding Spike proteins of SARS-CoV-2. We further examined it in conjunction with the docking results in response to the recently reported anti-AIDS drugs Lopinavir and ritonavir tablets, which have a poor effect on the treatment of novel coronavirus pneumonia and have toxic side effects. The results of the molecular docking indicate that Raltegravir, an antiviral HIV-drug (-7.68 kcal/mol), had a higher binding affinity than the other medications tested and there is no evidence of Lopinavir or Ritonavir binding completely to major targets such as 2AJF. This docking result suggests that the anti-HIV drug could aid in COVID-19 drug discovery and lopinavir and ritonavir tablets may be ineffective for treating SARS-CoV-2 infections. However, a further study that confirms antiviral activities by in vitro and in vivo evaluation study is required to repurpose these drugs against 2019-nCoV, providing scientists a heads-up on compounds that may be effective.

References

1. Li X, Wang W, Zhao X, Zai J, Zhao Q, Li Y, Chaillon A. Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol. 2020 [Epub ahead of print];92(5):501-11. doi: 10.1002/jmv.25701, PMID 32027035.
2. WHO Situation report dated on 03 May 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200503-covid-19-sitrep-104.pdf?sfvrsn=53328f46_2.
3. Weigelt J. Structural genomics-Impact on biomedicine and drug discovery. Exp Cell Res. 2010;316(8):1332-8. doi: 10.1016/j.yexcr.2010.02.041, PMID 20211166.
4. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146-57. doi: 10.2174/157340911795677602, PMID 21534921.
5. López-Vallejo F, Caulfield T, Martínez-Mayorga K, Giulianotti MA, Nefzi A, Houghten RA, Medina-Franco JL. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. Comb Chem High Throughput Screen. 2011;14(6):475-87. doi: 10.2174/138620711795767866, PMID 21521151.
6. Huang SY, Zou X. Advances and challenges in protein-ligand docking. Int J Mol Sci. 2010;11(8):3016-34. doi: 10.3390/ijms11083016, PMID 21152288.
7. Lipinski CA, Lombardo F et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4-17.
8. FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral Use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058,021906s053lbl.pdf.
9. Clinton health access initiative. HIV market report. the state of HIV treatment, testing, and prevention in low- and middle-income countries. Boston, 2019.
10. AbbVie. Kaletra prescribing information; 2020. (Available from: http://www.rxabbvie.com/pdf/kaletratabpi.
11. Mirza MU, Ahmad S, Abdullah I, Froeyen M. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease. Comp Biol Chem. 2020;89:107376. doi: 10.1016/j.compbiolchem.2020.107376.
12. Arunkumar B, Fernandez A, Laila SP, Nair AS. Molecular docking study of acyclovir and its derivatives as potent inhibitors in novel COVID-19. Int J Pharm Sci Res. 2020:4700-5.
13. Peele KA, Potla Durthi C, Srihansa T, Krupanidhi S, Ayyagari VS, Babu DJ, Indira M, Reddy AR, Venkateswarulu TC. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked. 2020;19:100345. doi: 10.1016/j.imu.2020.100345.
14. Noureddine O, Issaoui N, Al-Dossary O. DFT and molecular docking study of chloroquine derivatives as antiviral to coronavirus COVID-19. J King Saud Univ Sci. 2021;33(1). doi: 10.1016/j.jksus.2020.101248, PMID 101248.
15. Tariq A, Mateen RM, Afzal MS, Saleem M. Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. Int J Infect Dis. 2020;98:166-75. doi: 10.1016/j.ijid.2020.06.063, PMID 32579907.
16. Jiménez-Alberto A, Ribas-Aparicio RM, Aparicio-Ozores G, Castelán-Vega JA. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. Comp Biol Chem. 2020;88:107325. doi: 10.1016/j.compbiolchem.2020.107325.
17. Liang J, Karagiannis C, Pitsillou E, Darmawan KK, Ng K, Hung A, Karagiannis TC. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. Comp Biol Chem. 2020;89:107372. doi: 10.1016/j.compbiolchem.2020.107372.
18. Meyer-Almes FJ. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: virtual screening and structure based drug design. Comp Biol Chem. 2020;88:107351. doi: 10.1016/j.compbiolchem.2020.107351.
19. Yu JW, Wang L, Bao LD. Exploring the active compounds of traditional Mongolian medicine in intervention of novel coronavirus (COVID-19) based on molecular docking method. J Funct Foods. 2020;71:104016. doi: 10.1016/j.jff.2020.104016.
20. Peele KA, Potla Durthi C, Srihansa T, Krupanidhi S, Ayyagari VS, Babu DJ, Indira M, Reddy AR, Venkateswarulu TC. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked. 2020;19:100345. doi: 10.1016/j.imu.2020.100345.
21. Azim KF, Ahmed SR, Banik A, Khan MMR, Deb A, Somana SR. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: an integrative computational approach. Inform Med Unlocked. 2020;20:100367. doi: 10.1016/j.imu.2020.100367.
22. Bhati S. Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19. Heliyon. 2020;6(11):e05558. doi: 10.1016/j.heliyon.2020.e05558, PMID 33251371.
23. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47. doi: 10.1038/nrd.2015.37, PMID 26868298.
24. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606-16. doi: 10.1016/j.jinf.2013.09.029, PMID 24096239.
25. De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875-84. doi: 10.1128/AAC.03011-14, PMID 24841269.
26. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885-93. doi: 10.1128/AAC.03036-14, PMID 24841273.
27. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090-5. doi: 10.1016/S1473-3099(14)70920-X, PMID 25278221.
28. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766-88. doi: 10.1016/j.apsb.2020.02.008, PMID 32292689.
29. Bajad NG, Rayala S, Gutti G, Sharma A, Singh M, Kumar A, Singh SK. Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. Curr Res Pharmacol Drug Discov. 2021;2. doi: 10.1016/j.crphar.2021.100026, PMID 100026.
30. Mujwar S. Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2. Comput Biol Med. 2021;136:104748. doi: 10.1016/j.compbiomed.2021.104748.
31. Mahmudul H, Alam MS, Parvez KF, Azim AS, Imran T, Raihan A, Uddin SSU. Main protease inhibitors and drug surface hotspot for the treatment of COVID-19: drug repurposing and molecular docking approach; 2020.
32. Ragavan Rameshkumar M, Indu P, Arunagirinathan N, Venkatadri B, El-Serehy HA, Ahmad A. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study. 2020.
33. Xia ng R, Yu Z, Wang Y, Wang L, Huo S, Li Y, Liang R, Hao Q, Ying T, Gao Y, Yu F, Jiang S. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm Sin B. 2021. doi: 10.1016/j.apsb.2021.06.016, PMID 34249607.
34. Ahsan T, Sajib AA. Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor. Biochem Biophys Rep. 2021;26:100982. doi: 10.1016/j.bbrep.2021.100982.
35. Shaikh VS, Shaikh Y, Ahmed K. Lopinavir as a potential inhibitor for SARS-CoV-2 target protein: A molecular docking study. Available at SSRN 3596820. 2020. doi: 10.2139/ssrn.3596820.